X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DIVIS LABORATORIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DIVIS LABORATORIES GSK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 56.4 35.3 159.7% View Chart
P/BV x 10.1 5.7 176.6% View Chart
Dividend Yield % 1.3 0.9 144.7%  

Financials

 GSK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
DIVIS LABORATORIES
Mar-17
GSK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,8381,222 314.1%   
Low Rs2,637784 336.4%   
Sales per share (Unadj.) Rs354.2153.1 231.3%  
Earnings per share (Unadj.) Rs39.839.9 99.5%  
Cash flow per share (Unadj.) Rs42.944.6 96.1%  
Dividends per share (Unadj.) Rs30.0010.00 300.0%  
Dividend yield (eoy) %0.91.0 92.9%  
Book value per share (Unadj.) Rs236.9201.8 117.4%  
Shares outstanding (eoy) m84.70265.47 31.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.16.6 139.5%   
Avg P/E ratio x81.425.1 324.3%  
P/CF ratio (eoy) x75.522.5 335.7%  
Price / Book Value ratio x13.75.0 274.9%  
Dividend payout %75.425.0 301.4%   
Avg Mkt Cap Rs m274,216266,266 103.0%   
No. of employees `0004.79.7 48.2%   
Total wages/salary Rs m4,8304,687 103.0%   
Avg. sales/employee Rs Th6,387.04,175.0 153.0%   
Avg. wages/employee Rs Th1,028.3481.5 213.6%   
Avg. net profit/employee Rs Th717.11,089.3 65.8%   
INCOME DATA
Net Sales Rs m30,00040,643 73.8%  
Other income Rs m728749 97.2%   
Total revenues Rs m30,72841,392 74.2%   
Gross profit Rs m4,19014,460 29.0%  
Depreciation Rs m2631,233 21.3%   
Interest Rs m023 0.0%   
Profit before tax Rs m4,65513,953 33.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7443,349 52.1%   
Profit after tax Rs m3,36810,604 31.8%  
Gross profit margin %14.035.6 39.3%  
Effective tax rate %37.524.0 156.1%   
Net profit margin %11.226.1 43.0%  
BALANCE SHEET DATA
Current assets Rs m16,74240,105 41.7%   
Current liabilities Rs m7,2026,595 109.2%   
Net working cap to sales %31.882.5 38.6%  
Current ratio x2.36.1 38.2%  
Inventory Days Days52119 43.7%  
Debtors Days Days2181 25.8%  
Net fixed assets Rs m8,63519,995 43.2%   
Share capital Rs m847531 159.5%   
"Free" reserves Rs m19,22253,043 36.2%   
Net worth Rs m20,06953,574 37.5%   
Long term debt Rs m100-   
Total assets Rs m30,03861,585 48.8%  
Interest coverage xNM618.4-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.7 151.3%   
Return on assets %11.217.3 65.0%  
Return on equity %16.819.8 84.8%  
Return on capital %25.526.1 97.6%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m52835,384 1.5%   
Fx outflow Rs m7,19310,399 69.2%   
Net fx Rs m-6,66524,985 -26.7%   
CASH FLOW
From Operations Rs m2,36011,493 20.5%  
From Investments Rs m3,008-11,372 -26.5%  
From Financial Activity Rs m-5,108-93 5,486.1%  
Net Cashflow Rs m26028 916.5%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.8 86.4%  
FIIs % 23.8 19.0 125.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   102,036 31,796 320.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  NOVARTIS  PANACEA BIOTECH  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Cheap Valuation of PSU Banks and Key Stocks in Action Today(Pre-Open)

NSE PSU Bank Index surged 30% on 25th October 2017-the date when bank recapitalization of Rs 2.1 trillion was announced.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


May 18, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - SANOFI INDIA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS